Lyrica is the Pfizer brand name for pregabalin, a gabapentinoid that binds the alpha2-delta subunit of voltage-gated calcium channels to reduce nerve pain signaling. The FDA has approved pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain from spinal cord injury, and as an add-on treatment for partial-onset seizures. Pregabalin is a DEA Schedule V controlled substance, which means pharmacies apply refill-timing rules, quantity limits, and identification checks that do not apply to non-controlled generics like metformin or atorvastatin. Most prescriptions written for Lyrica in 2026 are filled with generic pregabalin rather than the branded capsule, because pharmacies substitute automatically unless the prescriber marks the prescription Dispense As Written.
Generic pregabalin has been available in the United States since July 2019, when the FDA approved versions from nine manufacturers after Pfizer's core patent expired. That competition collapsed the price: cash-paying patients who once faced list prices above $700 a month for brand Lyrica can now find 30-day supplies of generic pregabalin for $9 to $30 with a coupon at most chain pharmacies in 2026. Lyrica CR, the once-daily extended-release tablet the FDA approved in 2017, is a separate case. Generic competition for Lyrica CR remains far more limited than for the original capsule, and formulation patents may keep brand pricing in place into 2030, so patients on Lyrica CR should ask their pharmacist whether an extended-release generic is stocked before assuming the immediate-release generic price applies.
Pregabalin was not included in the first two rounds of drugs selected for Medicare price negotiation under the Inflation Reduction Act of 2022. Round 1 negotiated Maximum Fair Prices, covering drugs like Eliquis and Jardiance, took effect January 1, 2026; Round 2 prices, covering semaglutide products, take effect in 2027. Pregabalin's cost story runs differently: because a competitive generic market already drives the price down to single digits with a coupon, Medicare beneficiaries filling generic pregabalin typically pay far less than the negotiated brand prices on other drugs. Patients who specifically need brand Lyrica or Lyrica CR, and cannot use it affordably, should review Medicare eligibility rules for their plan and check whether Medicaid income limits in their state qualify them for wraparound drug coverage.
What Lyrica Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same lyrica can cost many times more at a hospital than at your local pharmacy:
2026 Lyrica Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, generic pregabalin) | $320 - $535/month without a coupon; $9 - $30/month with a coupon | Nearly all pregabalin prescriptions are filled as the generic; pharmacies substitute automatically unless marked Dispense As Written. |
| Pharmacy counter (retail, cash, brand Lyrica or Lyrica CR) | $750 - $900/month (Lyrica); $600 - $650/month (Lyrica CR) | Brand pricing applies when a prescriber requires brand-only dispensing or prescribes Lyrica CR, which has limited generic competition. |
| Medicare Part D (2026) | $1 - $10/month generic; higher for brand after prior authorization | Total Part D out-of-pocket spending across all drugs is capped at $2,100/year. |
| Commercial insurance | $5 - $50/month generic; $50 - $150+/month brand after PA | Brand Lyrica and Lyrica CR usually require prior authorization or step therapy with generic pregabalin first. |
| Medicaid | $1 - $4/prescription generic; PA required for brand | Nominal copay for generic pregabalin; brand requests typically need documented treatment failure. |
Retail figures reflect August 2026 GoodRx and SingleCare pharmacy pricing checks for generic pregabalin. Part D and commercial ranges depend on your plan's formulary tier and where you are in the benefit year.
Source: CMS Part D 2026 benefit design, GoodRx, SingleCare, Pfizer RxPathways
Why Hospitals Charge So Much
Inpatient pharmacies rarely stock brand-name Lyrica because hospital formularies default to the far cheaper generic pregabalin, but a hospital's per-dose charge for either version can run several times the outpatient retail rate. A single 75 mg pregabalin capsule that costs well under a dollar at retail when purchased as part of a $9 to $30 monthly coupon fill can appear on an itemized inpatient bill as $75 to $250 per day-equivalent supply once facility fees, pharmacy handling charges, and nursing administration markups are layered on top. Patients admitted for seizure management, post-surgical neuropathic pain, or fibromyalgia flare-ups who see pregabalin doses charged at hospital markup rates should request an itemized bill and compare the per-dose charge to the drug's wholesale acquisition cost, which for generic pregabalin runs well under a dollar per capsule in 2026.
Medicare Part A generally covers drugs administered during an inpatient stay as part of the diagnosis-related group payment, so patients with Original Medicare should not see a separate line-item bill for pregabalin given during an admission. Commercial insurers handle inpatient drug charges differently, often applying them toward the medical deductible and coinsurance rather than the Part D-style pharmacy copay, which is why the same pregabalin dose can cost dramatically more inside a hospital stay than it does at a retail pharmacy counter. If an itemized inpatient bill shows pregabalin priced far above its retail cash equivalent, ask the hospital billing office for the charge description master rate and consider using a medical bill analyzer to check whether the markup is negotiable.
Patient Assistance Programs
Pfizer, the manufacturer of Lyrica and Lyrica CR, runs a patient assistance program and a separate commercial copay savings card. Because generic pregabalin already costs $9 to $30 a month with a coupon at most pharmacies in 2026, these manufacturer programs matter most for patients who specifically need the brand product or Lyrica CR.
Patient assistance programs for Lyrica| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Pfizer RxPathways (Lyrica/Lyrica CR) | Free brand-name Lyrica or Lyrica CR for uninsured or government-insured patients at or below 300% FPL (2026) | pfizerrxpathways.com |
| LYRICA Co-Pay Savings Card | As low as $4 per prescription for commercially insured patients; up to $250 savings per fill, $3,000 maximum per year | lyrica.com/Co-Pay-Savings-Card |
| GoodRx / SingleCare Pregabalin Coupon | $9 - $30/month for generic pregabalin at participating pharmacies; no enrollment or income requirement | goodrx.com/pregabalin |
| NeedyMeds Drug Discount Card | Variable discount on generic pregabalin or brand Lyrica accepted at most US pharmacies | needymeds.org |
Manufacturer copay savings cards, including the LYRICA Co-Pay Savings Card, cannot be used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA health benefits under the federal anti-kickback statute (42 U.S.C. § 1320a-7b). Medicare and Medicaid beneficiaries who need brand Lyrica or Lyrica CR should apply for the Pfizer RxPathways patient assistance program instead, or ask their prescriber whether generic pregabalin is a safe substitute.
Source: Pfizer RxPathways, LYRICA Co-Pay Savings Card Program (lyrica.com), NeedyMeds.org, GoodRx
Medicare Part D
Medicare Part D covers pregabalin on nearly every 2026 formulary, typically on the lowest generic formulary tier with no prior authorization required for the immediate-release capsule. Total out-of-pocket spending across all Part D drugs combined, including pregabalin, is capped at $2,100 for 2026 under the Inflation Reduction Act of 2022. Because generic pregabalin's cash price already sits below $30 a month at most pharmacies, many Part D beneficiaries pay a flat generic copay of $1 to $10 rather than coinsurance tied to that annual cap.
Brand-name Lyrica and Lyrica CR sit on a higher formulary tier and commonly require prior authorization or step therapy showing that generic pregabalin failed or was not tolerated. Plans use this rule because a chemically identical generic already exists at a fraction of the brand price; without documented treatment failure, most Part D plans will deny a brand-name claim and default the patient to the covered generic. Prescribers can request a formulary exception if a patient has a documented medical reason, such as an inactive-ingredient allergy, that generic capsules do not accommodate.
Original Medicare beneficiaries can also enroll in the Medicare Prescription Payment Plan, which spreads a year's Part D out-of-pocket costs into monthly installments instead of one large charge at the pharmacy counter. That option matters more for patients paying brand Lyrica CR copays than for those filling the inexpensive generic, since a $2,100 annual cap is unlikely to matter much for a $10-a-month generic prescription.
Common Lyrica Billing Errors
If a pregabalin or Lyrica bill looks higher than the figures above, check for these common errors before paying:
- Pharmacy billed the brand-name Lyrica NDC and charged a brand copay even though generic pregabalin was actually dispensed. Compare the National Drug Code (NDC) printed on the label to your insurer's explanation of benefits.
- Prior authorization for brand Lyrica or Lyrica CR was never submitted, so the pharmacy defaulted to the full cash price instead of running the claim through Medicare Part D or commercial insurance.
- Early-refill rejection at the counter, common because pregabalin is a DEA Schedule V controlled substance with strict refill-timing rules, was mistaken for a coverage denial rather than a controlled-substance dispensing rule.
- Lyrica CR's once-daily quantity was billed as though it were the twice-daily immediate-release capsule, doubling the copay for the same 30-day supply.
- A GoodRx, SingleCare, or manufacturer coupon that should have brought the price to $9 to $30 a month was not applied at the register, leaving the patient paying the full $320 to $535 cash price.
- Coinsurance was charged on a Part D claim after the patient had already crossed the $2,100 annual out-of-pocket cap for 2026.
Frequently Asked Questions
Is there a generic for Lyrica?
Yes. Generic pregabalin has been available since July 2019, when the FDA approved versions from nine manufacturers after Pfizer's Lyrica patent expired. Generic pregabalin is chemically identical to brand Lyrica and typically costs $9 to $30 for a 30-day supply with a GoodRx or SingleCare coupon in 2026, compared to $750 or more for the brand capsule without insurance. Lyrica CR, the extended-release version, has more limited generic competition and may stay brand-priced into 2030.
How do I apply for the Pfizer patient assistance program for Lyrica?
Visit pfizerrxpathways.com or call 1-844-989-PATH (7284) to apply for Pfizer RxPathways. You will need proof of household income at or below 300 percent of the federal poverty level, proof that you are uninsured or covered by Medicare, a valid prescription, and your prescriber's signature on the enrollment form. Approved patients receive free brand Lyrica or Lyrica CR shipped to their prescriber's office; commercially insured patients are not eligible and should use the LYRICA Co-Pay Savings Card instead.
Can I use the Lyrica savings card with Medicare?
No. The LYRICA Co-Pay Savings Card, like nearly all manufacturer coupon programs, cannot be used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA health benefits under the federal anti-kickback statute. Medicare beneficiaries who need brand Lyrica or Lyrica CR should apply for the Pfizer RxPathways patient assistance program instead, or ask their prescriber about switching to generic pregabalin, which most Medicare Part D plans cover on the lowest formulary tier.
What if my insurance denies coverage for Lyrica or Lyrica CR?
Request the written denial notice, then file a formal appeal (a Part D redetermination for Medicare, or a standard appeal for commercial insurance) within 60 days with your prescriber's supporting documentation. If the denial was based on step therapy, ask your prescriber to file a formulary exception showing that generic pregabalin failed or is not appropriate. If appeals do not work, generic pregabalin itself, covered by nearly every plan, is available for $9 to $30 a month with a coupon and may be a faster fix than a lengthy appeal.
Does the Inflation Reduction Act's Maximum Fair Price apply to Lyrica?
No. Pregabalin was not selected for either the first or second round of Medicare drug price negotiation under the Inflation Reduction Act of 2022, so there is no negotiated Maximum Fair Price for Lyrica in 2026. Instead, Medicare Part D beneficiaries filling pregabalin fall under the general 2026 Part D annual out-of-pocket cap of $2,100, and most pay far less than that because generic pregabalin already costs under $30 a month with a coupon.
What does Lyrica cost without insurance at the pharmacy counter in 2026?
Brand-name Lyrica costs roughly $750 to $900 per month without insurance in 2026, and Lyrica CR runs about $600 to $650 per month. Generic pregabalin, which is what most pharmacies dispense by default, costs $320 to $535 for a 30-day supply without a coupon, or as little as $9 to $30 with a GoodRx or SingleCare coupon at chains like Walmart, Kroger, or Walgreens.
Do I qualify for the Pfizer RxPathways patient assistance program?
You may qualify if your household income is at or below 300 percent of the federal poverty level in 2026 (for example, $47,880 for a household of one or $99,000 for a household of four), you are uninsured or covered by Medicare, and you have a valid prescription for an FDA-approved use of Lyrica or Lyrica CR. Commercially insured patients do not qualify for this patient assistance program and should use the manufacturer copay card instead.
What's the difference between Lyrica, Lyrica CR, and generic pregabalin?
Lyrica is Pfizer's brand name for immediate-release pregabalin capsules, typically taken two or three times a day. Lyrica CR is a once-daily extended-release tablet the FDA approved in 2017. Generic pregabalin is the chemically identical, FDA-approved generic version of the original immediate-release capsule, available since 2019 and dispensed automatically at most pharmacies unless the prescriber specifies brand only. Lyrica CR has far less generic competition than the immediate-release product, so it typically costs much more.
